Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Merus N.V. - Common Shares
(NQ:
MRUS
)
94.88
+0.46 (+0.49%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 24, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merus N.V. - Common Shares
< Previous
1
2
3
4
Next >
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
October 24, 2025
From
Merus N.V.
Via
GlobeNewswire
HALPER SADEH LLC ENCOURAGES MTSR, HOLX, MRUS SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
October 23, 2025
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
From
Halper Sadeh LLC
Via
GlobeNewswire
Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
October 23, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 14, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 13, 2025
From
Merus N.V.
Via
GlobeNewswire
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates PINC, ODP, PRO, MRUS on Behalf of Shareholders
October 09, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates EA, MRUS, BRY, SMLR on Behalf of Shareholders
October 07, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq - EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq - BRY), Semler Scientific, Inc. (Nasdaq – SMLR)
October 07, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRO, EA, MRUS on Behalf of Shareholders
October 04, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA and MRUS on Behalf of Shareholders
October 01, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
September 30, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRUS, BRY, SMLR on Behalf of Shareholders
September 29, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq – EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq – BRY), Semler Scientific, Inc. (Nasdaq – SMLR)
September 29, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
MRUS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Merus N.V. Is Fair to Shareholders
September 29, 2025
From
Halper Sadeh LLC
Via
Business Wire
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
September 29, 2025
From
Genmab A/S
Via
Business Wire
Merus to Present at the 2025 Wells Fargo Healthcare Conference
August 28, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus to Present at the Canaccord Genuity 45th Annual Growth Conference
August 06, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update
August 05, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus N.V. Announces Pricing of Public Offering of Common Shares
June 04, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus N.V. Announces Proposed Public Offering of Common Shares
June 03, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus to Present at Upcoming Investor Conferences
May 27, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
May 22, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus Announces the Journal Publication of Petosemtamab Mechanism of Action
May 15, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus to Present at BofA Securities 2025 Health Care Conference
May 08, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update
May 07, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
April 23, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
April 01, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
February 27, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus to Present at Upcoming Investor Conferences
February 25, 2025
From
Merus N.V.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.